Journal Mobile Options
Table of Contents
Vol. 69, No. 5, 2000
Issue release date: September–October 2000
Psychother Psychosom 2000;69:240–243

Cognitive Therapy by Allocation versus Cognitive Therapy by Preference in the Treatment of Panic Disorder

Bakker A. · Spinhoven P. · van Balkom A.J.L.M. · Vleugel L. · van Dyck R.
aDepartment of Psychiatry and bInstitute for Research in Extramural Medicine, Vrije Universiteit, Amsterdam, and cDepartment of Clinical and Health Psychology and Department of Psychiatry, Leiden University, Leiden, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Little is known about the influence of preference for a given therapy or preference against a modality of treatment on the outcome of that treatment. Results so far have been conflicting. The primary aim of this study was to investigate possible differences in outcome between panic disorder patients treated with preferred cognitive therapy and patients treated by randomization with the same intervention. Methods: A 12-week study comparing 35 patients treated by allocation with 31 patients treated by preference. Results: There were no differences at pretest between the two conditions on demographic or outcome measures. Outcome was assessed with measurements rating the panic frequency and severity of agoraphobia, general anxiety and depression. Both conditions improved significantly on nearly all ratings. There were no significant differences demonstrable between the two conditions on any of the outcome measures. Conclusion: Preference for a given therapy is not a powerful moderator of effect in the psychological treatment of panic disorder.

Copyright © 2000 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. van Dyck R, Spinhoven P: Does preference for type of treatment matter? Behav Modif 1997;21:172–186.
  2. Bakker A, van Dyck R, Spinhoven P, van Balkom AJLM: Paroxetine, clomipramine and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry, in press.
  3. Clark DM: A cognitive approach to panic. Behav Res Ther 1986;24:461–470.
  4. Guy W: ECDEU Assessment Manual for Psychopharmacology. US Department Health, Education, and Welfare publication (ADM) 76-338. Rockville, National Institute of Mental Health, 1976, pp 218–222.
  5. Hamilton M: Diagnosis and rating of anxiety. Br J Psychiatry 1969;3:76–79.
  6. Sheehan DV: The Anxiety Disease. New York, Scribner’s Sons, 1983, pp 144–153.
  7. Chambless DL, Caputo GC, Bright P, Gallagher R: Assessment of fear in agoraphobics: The Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol 1984;52:1090–1097.
  8. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
  9. Fava GA, Savron G, Zielezny M, Grandi S, Rafanelli C, Conti S: Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatr Scand 1997;95:306–312.
  10. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SA, Shear MK, Woods SW, Gorman JG: Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry 1998;155:43–47.
  11. Ananth J: Treatment-resistant depression. Psychother Psychosom 1998;67:61–70.
  12. Antonuccio DO, Danton WG, DeNelsky GY, Greenberg RP, Gordon JS: Raising questions about antidepressants. Psychother Psychosom 1999;68:3–14.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00